Infliximab-induced lupus or rheumatoid arthritis (RA) overlapping with systemic lupus erythematosus (SLE) unmasked by infliximab.
Novak
S
S
Cikes
N
N
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000473:pathology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D000069285:Infliximab; D008180:Lupus Erythematosus, Systemic / Q000209:etiology* / Q000473:pathology; D008727:Methotrexate / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D028761:Withholding Treatment
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab; D008775:Methylprednisolone; D008727:Methotrexate